3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
7
Gastrointestinal
2
Thoracic
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Neoplasms
2
Prostatic Neoplasms
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Meningioma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Specimen Handling
4
Gemcitabine
3
Cyclophosphamide
3
temsirolimus
2
fludarabine
2
Trastuzumab
2
Temozolomide
2
Sirolimus
2
Radiosurgery
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Leucovorin
2
Injections
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Blood Specimen Collection
2
Biopsy
2
Bevacizumab
2
Azacitidine
2
vandetanib
1
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Hematologic Tests
×
CNS
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled